OncoMatch/Clinical Trials/NCT06793332
BrAin Metastasis in TripLe Negateive Breast Cancer: IvoneScimab and Trop2 ADC
Is NCT06793332 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Ivonescimab Combined With TROP2 ADC for triple-negative breast cancer (tnbc).
Treatment: Ivonescimab Combined With TROP2 ADC — This study is a single-center, prospective, single-arm clinical trial, which intends to enroll patients with triple-negative breast cancer with brain metastases to receive ivonescimab combined with TROP2 ADC (such as sacituzumab govitecan) treatment until disease progression, intolerable toxicity, withdrawal of informed consent, or the investigator deems it necessary to discontinue the medication, and to collect data on the drug's efficacy and safety.
Check if I qualifyExtracted eligibility criteria
Cancer type
Triple-Negative Breast Cancer
Breast Carcinoma
Disease stage
Metastatic disease required
unresectable locally advanced, recurrent or metastatic triple-negative breast cancer
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: taxane
have failed treatment with taxane drugs
Cannot have received: monoclonal or bispecific antibodies containing anti-VEGF-A and anti-PD-1/PD-L1/CTLA-4
Previously used monoclonal or bispecific antibodies containing anti-VEGF-A and anti-PD-1/PD-L1/CTLA-4
Cannot have received: TROP2 antibody-drug conjugate
previously used TROP2 ADC drugs
Cannot have received: whole brain radiotherapy
Exception: allowed if >2 weeks before treatment
Received whole brain radiotherapy...within 2 weeks before the treatment with the investigational drug
Cannot have received: chemotherapy
Exception: allowed if >2 weeks before treatment
Received...chemotherapy...within 2 weeks before the treatment with the investigational drug
Cannot have received: surgery
Exception: allowed if >2 weeks before treatment
Received...surgery within 2 weeks before the treatment with the investigational drug
Cannot have received: targeted therapy
Exception: allowed if >1 week before treatment
received targeted therapy...within 1 week before the treatment
Cannot have received: endocrine therapy
Exception: allowed if >1 week before treatment
received...endocrine therapy within 1 week before the treatment
Lab requirements
Blood counts
adequate hematologic function required
Kidney function
adequate renal function required
Liver function
adequate hepatic function required
adequate hematologic, hepatic, and renal function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify